Skip to content
MarketScale
‹ Back to IndustriesHealthcare

EMR Strategy, Consulting, and Career Pivots with MedSys Co-Founder Mark Embry

EMR implementations now drive care quality and hospital economics, with systems costing up to $100M. Mark Embry, co-founder of MedSys Group, discusses how EMR consulting evolved into strategic healthcare transformation work, emphasizing that user adoption and workflow change—not just technology—determine success.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from I Don't Care on MarketScale.

By Kevin Stevenson · Digital HealthEmrHealthcare ConsultingHealthcare It
Share

Key takeaways

01

EMR consulting is now strategic in healthcare transformation.

02

User adoption is critical for EMR success, beyond technology.

03

Founders should consider team, culture, and timing in exit strategies.

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Electronic medical records (EMRs) have moved from a back-office upgrade to a frontline determinant of care quality, clinician burnout, and hospital economics. With U.S. hospitals often spending tens to hundreds of millions—sometimes exceeding $100 million—on EMR implementations, the stakes have never been higher for getting both the technology and the human adoption right. As healthcare continues shifting toward interoperability, outpatient care, and data-driven decision-making, the conversation around EMRs is no longer technical—it’s strategic.

So what does it really take to build a business in the EMR space—and more importantly, how do you know when it’s time to walk away from it?

Welcome to I Don’t Care, hosted by Dr. Kevin Stevenson. In the latest episode, Dr. Stevenson sits down with Mark Embry, partner and co-founder of MedSys Group, to unpack decades of experience in healthcare technology consulting, the evolution of EMR implementation, and the personal side of exiting a company after 30 years.

Top insights from the talk…

  • How EMR consulting evolved from niche staffing to mission-critical healthcare transformation work: What started as staffing has become strategic work shaping how health systems operate.
  • Why user adoption—not just technology—is the biggest determinant of EMR success: Without workflow change and clinician buy-in, even the best systems fall short.
  • What founders should consider when transitioning out of a business they’ve built from scratch: A strong exit balances financial outcomes with team, culture, and timing.

Mark Embry is the co-founder and EVP of Client Relationships at MedSys Group, where he has spent nearly three decades leading EMR advisory, implementation, and healthcare IT consulting services for providers across the U.S. He played a key role in building the company from its origins as Genesys Group into a nationally recognized firm supporting major initiatives, including federal EHR modernization projects with the DOD and VA. With over 20 years in IT consulting, Embry specializes in strategic partnerships, healthcare technology transformation, and scaling consulting organizations to deliver high-impact client outcomes.

Article written by MarketScale.

Featured companies

I Don't Care

Part of this channel

I Don't Care

Candid healthcare leadership conversations with Kevin Stevenson

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

Kevin Stevenson
Kevin StevensonTop Hospital Administrator & Healthcare COO, I Don't Care
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Experts

Kevin Stevenson
Kevin Stevenson

Host, I Don't Care

I Don't Care

Kevin Stevenson hosts the podcast 'I Don't Care', where he interviews key figures in healthcare. He focuses on the logistics behind healthcare systems, allowing medical professionals to concentrate on patient care.

ME
Mark Embry

Co-Founder and EVP of Client Relationships

MedSys Group

Mark Embry is the co-founder and EVP of Client Relationships at MedSys Group. He has nearly three decades of experience in leading EMR advisory, implementation, and healthcare IT consulting services across the U.S. Embry specializes in strategic partnerships and healthcare technology transformation.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512